

Christoph Kessel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2700253/publications.pdf>

Version: 2024-02-01

46
papers

1,305
citations

394421

19
h-index

361022

35
g-index

49
all docs

49
docs citations

49
times ranked

1984
citing authors

#	ARTICLE	IF	CITATIONS
1	MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. <i>Rheumatology</i> , 2022, 61, 3082-3092.	1.9	12
2	Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e329-e337.	3.9	33
3	Soluble interleukin-2 receptor serum levels facilitate prediction of relapses in subgroups of patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2022, , .	1.9	4
4	Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 990-997.	0.9	13
5	An Immunological Axis Involving Interleukin 1 β and Leucine-Rich- α 2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial. <i>Journal of Clinical Immunology</i> , 2022, 42, 1330-1341.	3.8	4
6	A dysregulated interleukin-18 α -interferon- γ -CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 60, 5165-5174.	1.9	20
7	Serum biomarkers confirming stable remission in inflammatory bowel disease. <i>Scientific Reports</i> , 2021, 11, 6690.	3.3	25
8	Application of systems biology-based in silico tools to optimize treatment strategy identification in Still α 's disease. <i>Arthritis Research and Therapy</i> , 2021, 23, 126.	3.5	19
9	Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline. <i>Pediatric Rheumatology</i> , 2021, 19, 64.	2.1	11
10	Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e563-e573.	3.9	14
11	Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers. <i>Arthritis and Rheumatology</i> , 2021, 73, 1791-1799.	5.6	36
12	Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 391-406.	1.9	21
13	Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 499-505.	5.6	11
14	Synergistic Signaling of TLR and IFN γ Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 526-539.	5.6	38
15	Innately Adaptive or Truly Autoimmune: Is There Something Unique About Systemic Juvenile Idiopathic Arthritis?. <i>Arthritis and Rheumatology</i> , 2020, 72, 210-219.	5.6	33
16	MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020, 59, 2392-2401.	1.9	14
17	Gene-Dose Effect of MEFV Gain-of-Function Mutations Determines ex vivo Neutrophil Activation in Familial Mediterranean Fever. <i>Frontiers in Immunology</i> , 2020, 11, 716.	4.8	23
18	Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1107-1113.	0.9	18

#	ARTICLE	IF	CITATIONS
19	S100 Proteins in Autoinflammation. , 2019, , 149-163.		2
20	SAT0497â€¦CLINICAL PICTURE OF 7 PAPA PATIENTS FOLLOWED IN A SINGLE PEDIATRIC RHEUMATOLOGIC CENTER. , 2019, , .		0
21	AB1069â€¦HYPERZINCAEMIA AND HYPERCALPROTECTINEMIA SYNDROME: MORE THAN JUST AUTOINFLAMMATION?. , 2019, , .		0
22	Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation. Journal of Visualized Experiments, 2019, , .	0.3	0
23	Monocyteâ€œDerived Interleukinâ€œ1 ^{Î²} As the Driver of S100A12â€œInduced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease. Arthritis and Rheumatology, 2019, 71, 792-804.	5.6	50
24	Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort. Arthritis Research and Therapy, 2018, 20, 276.	3.5	32
25	S100A12 Serum Levels and PMN Counts Are Elevated in Childhood Systemic Vasculitides Especially Involving Proteinase 3 Specific Anti-neutrophil Cytoplasmic Antibodies. Frontiers in Pediatrics, 2018, 6, 341.	1.9	16
26	The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Molecular and Cellular Pediatrics, 2018, 5, 7.	1.8	39
27	Calcium and zinc tune autoinflammatory Toll-like receptor 4 signaling by S100A12. Journal of Allergy and Clinical Immunology, 2018, 142, 1370-1373.e8.	2.9	29
28	Proteomics in Chronic Arthritisâ€œWill We Finally Have Useful Biomarkers?. Current Rheumatology Reports, 2018, 20, 53.	4.7	2
29	Proinflammatory Cytokine Environments Can Drive Interleukinâ€œ17 Overexpression by $\gamma\delta$ T Cells in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2017, 69, 1480-1494.	5.6	71
30	Correlation of Secretory Activity of Neutrophils With Genotype in Patients With Familial Mediterranean Fever. Arthritis and Rheumatology, 2016, 68, 3010-3022.	5.6	34
31	Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?. Arthritis Research and Therapy, 2016, 18, 163.	3.5	48
32	From bench to bedside and back again: translational research in autoinflammation. Nature Reviews Rheumatology, 2015, 11, 573-585.	8.0	60
33	A Single Functional Group Substitution in C5a Breaks B Cell and T Cell Tolerance and Protects Against Experimental Arthritis. Arthritis and Rheumatology, 2014, 66, 610-621.	5.6	22
34	Proinflammatory S100A12 Can Activate Human Monocytes via Toll-like Receptor 4. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1324-1334.	5.6	146
35	Phagocyte-derived S100 proteins in autoinflammation: Putative role in pathogenesis and usefulness as biomarkers. Clinical Immunology, 2013, 147, 229-241.	3.2	142
36	Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Annals of the Rheumatic Diseases, 2013, 72, 652-658.	0.9	137

#	ARTICLE	IF	CITATIONS
37	Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunological Reviews, 2010, 233, 9-33.	6.0	83
38	Multimerization of Peptide Mimotopes for Blocking of Factor VIII Neutralizing Antibodies. ChemMedChem, 2009, 4, 1364-1370.	3.2	7
39	Epitope Mapping of FIX Inhibitors Identify Contact Residues in the Protease Domain.. Blood, 2009, 114, 3172-3172.	1.4	0
40	Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Molecular Immunology, 2008, 46, 8-15.	2.2	20
41	Peptide Multimers for Binding of Factor VIII Inhibitors.. Blood, 2008, 112, 1224-1224.	1.4	0
42	Peptide mimotopes selected with HIV-1- blocking monoclonal antibodies against CCR5 represent motifs specific for HIV-1 entry. Immunology and Cell Biology, 2007, 85, 511-517.	2.3	8
43	Response to Anti CD20 Monoclonal Antibody Rituximab® and Epitope Mapping of Inhibitory Antibodies in Patients with Acquired Haemophilia.. Blood, 2006, 108, 1044-1044.	1.4	0
44	Epitope Mapping of Inhibitors in Acquired Hemophilia by Phage Display.. Blood, 2005, 106, 3202-3202.	1.4	0
45	Ligand Mediated Targeting of FVIII Inhibitor Specific Primary B Cells Via Surface Immunoglobulin.. Blood, 2005, 106, 3206-3206.	1.4	4
46	Inhibitor Epitopes Identified from Inhibitor Positive Plasma of a Hemophilia B Patient Change during ITT.. Blood, 2005, 106, 3201-3201.	1.4	0